ClinicalTrials.gg
TerminatedNCT03126097Updated Sep 1, 2017

A Study to Investigate the Interaction Between JNJ-64155806 and Ethinylestradiol/Drospirenone in Healthy Females

A Phase 1 interventional study of JNJ-64155806 150 mg and Ethinylestradiol/drospirenone 0.02 mg/3 mg in Healthy, sponsored by Janssen Research & Development, LLC. Terminated at 1 site in United States. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-09-01.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 1, Interventional, and Treatment

Why this study was terminated
Study stopping rules were met.

From the registry’s dates

  • Primary completion was May 2017, 9 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
Female
01

Study summary

The primary purpose of this study is to evaluate the effect of single and multiple doses of JNJ-64155806 on the steady-state pharmacokinetics (PK) of ethinylestradiol and drospirenone and vice versa in healthy female participants.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.

Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be female of with a normal menstrual cycle, not using oral in the 30 days prior to screening
  • Participant must have a (BMI; weight in kilogram (kg) divided by the square of height in meters [m]) of 18.0 to 30.0 kg/m\^2, extremes included, and a body weight not less than (\<) 50.0 kg
  • Participant must be willing and able to adhere to the requirements, instructions, and prohibitions and restrictions specified in this protocol, and is likely to complete the study as planned
  • Participant must be healthy on the basis of physical examination, medical history, vital signs, 12-lead (ECG), and clinical laboratory tests performed at screening. If the results of the biochemistry panel, hematology, or urinalysis are outside the normal reference ranges, the participant may be included only if the investigator judges the abnormalities or deviations from normal to be not . This determination must be recorded in the participant's source documents and initialed by the investigator
  • Participants must be willing to start ethinylestradiol/drospirenone contraception during the COCP lead-in and JNJ-64155806 + COCP coadministration phases

Exclusion criteria

Exclusion Criteria:

  • Participant is a woman who is pregnant as confirmed by a positive beta human chorionic gonadotropin (beta-hCG) laboratory test, or who was pregnant within 6 months prior to study start, or who is breast-feeding, or who is planning to become pregnant from signing of the form (ICF) until 90 days after the last dose of study drug
  • Participant with of less than (\<) 90 milliliter per minute (mL/min) (Chronic Kidney Disease Epidemiology Collaboration [] equation)
  • Participant with a cardiovascular, respiratory, renal, gastrointestinal, hematologic, neurologic (syncope or seizures), thyroid, or any other medical illness or psychiatric disorder, as determined by the investigator and/or sponsor's medical monitor
  • Participant has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant (example, compromise the well-being), or that could prevent, limit, or confound the protocol-specified assessments
  • Participant with currently active gynecological disorders including, but not limited to, vaginal bleeding without an obvious reason and hyperprolactinemia with or without galactorrhea
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    JNJ-64155806+COCP+JNJ-64155806 with COCP

    Participants will receive JNJ-64155806 150 milligram (mg) twice daily (BID) under fed conditions on Days 1 to 7 \[JNJ-64155806 Alone Phase\] followed by a 10-day washout phase; followed by Ethinylestradiol/drospirenone 0.02 mg/3 mg given as a combined oral contraceptive pill (COCP) once daily (QD) on Days 18 to 41 and COCP placebo QD on Days 42 to 45 \[COCP Lead-in Phase\]; further followed by COCP QD on Days 46 to 69 (on Days 59 to 66 under fed condition), JNJ-64155806 150 mg BID (under fed conditions) on Days 60 to 66, and COCP placebo QD on Days 70 to 73 \[JNJ-64155806 + COCP Co-administration Phase\].

    Drug: JNJ-64155806 150 mg · Drug: Ethinylestradiol/drospirenone 0.02 mg/3 mg · Drug: COCP Placebo

Interventions

  • DrugJNJ-64155806 150 mg

    JNJ-64155806 150 mg (3\*50 mg tablet) twice daily will be administered under fed conditions on Days 1 to 7 \[JNJ-64155806 Alone Phase\] and on Days 60 to 66 \[JNJ-64155806 + COCP Coadministration Phase\].

  • DrugEthinylestradiol/drospirenone 0.02 mg/3 mg

    Each tablet contains 3 mg drospirenone and 0.02 mg ethinylestradiol administered as combined oral contraceptive pill (COCP) given on Days 18 to 41 (lead-in phase), Days 46 to 69 (coadministration phase - Days 59 to 66 under fed conditions).

  • DrugCOCP Placebo

    Participant will receive COCP placebo tablets once daily on Days 42 to 45 (lead-in phase) and Days 70 to 73 (JNJ-64155806 + COCP coadministration phase).

06

What researchers measure

Primary outcomes

  1. Trough Plasma Concentration (Ctrough) for Ethinylestradiol

    The Ctrough is the plasma concentration before dosing.

    Time frame: Days 57, 58, 59, 60, 66

  2. Trough Plasma Concentration (Ctrough) for Drospirenone

    The Ctrough is the plasma concentration before dosing.

    Time frame: Days 57, 58, 59, 60, 66

  3. Minimum Observed Plasma Concentration (Cmin) for Ethinylestradiol

    The Cmin is the minimum observed plasma concentration.

    Time frame: Days 59, 60, 66: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, and 24 hours postdose

  4. Minimum Observed Plasma Concentration (Cmin) for Drospirenone

    The Cmin is the minimum observed plasma concentration.

    Time frame: Days 59, 60, 66: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, and 24 hours postdose

  5. Maximum Observed Plasma Concentration (Cmax) for Ethinylestradiol

    The Cmax is the maximum observed plasma concentration.

    Time frame: Days 59, 60, 66: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, and 24 hours postdose

  6. Maximum Observed Plasma Concentration (Cmax) for Drospirenone

    The Cmax is the maximum observed plasma concentration.

    Time frame: Days 59, 60, 66: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, and 24 hours postdose

  7. Time to Reach Maximum Observed Plasma Concentration (Tmax) for Ethinylestradiol

    The Tmax is defined as actual sampling time to reach maximum observed analyte concentration.

    Time frame: Days 59, 60, 66: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, and 24 hours postdose

  8. Time to Reach Maximum Observed Plasma Concentration (Tmax) for Drospirenone

    The Tmax is defined as actual sampling time to reach maximum observed analyte concentration.

    Time frame: Days 59, 60, 66: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, and 24 hours postdose

  9. Average Plasma Concentration (C24h) at 24hours for Ethinylestradiol

    C24h is observed analyte concentration at 24 hours.

    Time frame: Days 59, 60, 66

  10. Average Plasma Concentration (C24h) at 24hours for Drospirenone

    C24h is observed analyte concentration at 24 hours.

    Time frame: Days 59, 60, 66

  11. Average Plasma Concentration (Cavg) for Ethinylestradiol

    Cavg is average analyte concentration at steady state, calculated as: AUC24h/24 hours at steady state \[24 hours equal to (=) dosing interval\].

    Time frame: Days 59, 60, 66

  12. Average Plasma Concentration (Cavg) for Drospirenone

    Cavg is average analyte concentration at steady state, calculated as: AUC24h/24 hours at steady state \[24 hours equal to (=) dosing interval\].

    Time frame: Days 59, 60, 66

  13. Area Under the Plasma Concentration-time Curve From Time Zero to 24 Hours (AUC[0-24h]) for Ethinylestradiol

    The AUC(0-24h) is the area under the plasma concentration time curve from time zero to 24 hours.

    Time frame: Days 59, 60, 66

  14. Area Under the Plasma Concentration-time Curve From Time Zero to 24 Hours (AUC[0-24h]) for Drospirenone

    The AUC(0-24h) is the area under the plasma concentration time curve from time zero to 24 hours.

    Time frame: Days 59, 60, 66

  15. Fluctuation Index (FI) for Ethinylestradiol

    FI is the percentage fluctuation (variation between maximum and minimum concentration at steady state), calculated as: 100\*(\[Cmax-Cmin\]/Cavg).

    Time frame: Days 59, 60, 66

  16. Fluctuation Index (FI) for Drospirenone

    FI is the percentage fluctuation (variation between maximum and minimum concentration at steady state), calculated as: 100\*(\[Cmax-Cmin\]/Cavg).

    Time frame: Days 59, 60, 66

  17. Ratio of Cmin Values Between Test and Reference (Ratio Cmin,test/ref) for Ethinylestradiol

    Ratio Cmin,test/ref is the ratio of individual Cmin values between test and reference treatment. Test is Day 60 (JNJ-64155806 single dose + ethinylestradiol/drospirenone) or Day 66 (JNJ-64155806 multiple dose + ethinylestradiol/drospirenone) and Reference is Day 59 (ethinylestradiol/drospirenone alone).

    Time frame: Days 59, 60, 66

  18. Ratio of Cmin Values Between Test and Reference (Ratio Cmin,test/ref) for Drospirenone

    Ratio Cmin,test/ref is the ratio of individual Cmin values between test and reference treatment. Test is Day 60 (JNJ-64155806 single dose + ethinylestradiol/drospirenone) or Day 66 (JNJ-64155806 multiple dose + ethinylestradiol/drospirenone) and Reference is Day 59 (ethinylestradiol/drospirenone alone).

    Time frame: Days 59, 60, 66

  19. Ratio of Cmax Values Between Test and Reference Treatment (Ratio Cmax,test/ref) for Ethinylestradiol

    Ratio Cmax,test/ref is the ratio of individual Cmax values between test and reference treatment. Test is Day 60 (JNJ-64155806 single dose + ethinylestradiol/drospirenone) or Day 66 (JNJ-64155806 multiple dose + ethinylestradiol/drospirenone) and Reference is Day 59 (ethinylestradiol/drospirenone alone).

    Time frame: Days 59, 60, 66

  20. Ratio of Cmax Values Between Test and Reference Treatment (Ratio Cmax,test/ref) for Drospirenone

    Ratio Cmax,test/ref is the ratio of individual Cmax values between test and reference treatment. Test is Day 60 (JNJ-64155806 single dose + ethinylestradiol/drospirenone) or Day 66 (JNJ-64155806 multiple dose + ethinylestradiol/drospirenone) and Reference is Day 59 (ethinylestradiol/drospirenone alone).

    Time frame: Days 59, 60, 66

  21. Ratio of AUC(0-24h) Values Between Test and Reference (Ratio AUC[0-24h],test/ref) for Ethinylestradiol

    Ratio AUC(0-24h),test/ref is the ratio of individual AUC(0-24h) values between test and reference treatment. Test is Day 60 (JNJ-64155806 single dose + ethinylestradiol/drospirenone) or Day 66 (JNJ-64155806 multiple dose + ethinylestradiol/drospirenone) and Reference is Day 59 (ethinylestradiol/drospirenone alone).

    Time frame: Days 59, 60, 66

  22. Ratio of AUC(0-24h) Values Between Test and Reference Treatment (Ratio AUC[0-24h],test/ref) for Drospirenone

    Ratio AUC(0-24h),test/ref is the ratio of individual AUC(0-24h) values between test and reference treatment. Test is Day 60 (JNJ-64155806 single dose + ethinylestradiol/drospirenone) or Day 66 (JNJ-64155806 multiple dose + ethinylestradiol/drospirenone) and Reference is Day 59 (ethinylestradiol/drospirenone alone).

    Time frame: Days 59, 60, 66

Secondary outcomes

  1. Number of Participants With Adverse Events as a Measure of Safety and Tolerability

    An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.

    Time frame: From Signing of Informed Consent Form (ICF) till End of Study (Day 73)

  2. Minimum Observed Plasma Concentration (Cmin) for JNJ-64155806

    The Cmin is the minimum observed plasma concentration.

    Time frame: Days 1, 7, 60, 66

  3. Maximum Observed Plasma (Cmax) for JNJ-64155806

    The Cmax is the maximum observed plasma concentration.

    Time frame: Days 1, 7, 60, 66

  4. Time to Reach Maximum Observed Plasma Concentration (Tmax) for JNJ-64155806

    The Tmax is defined as actual sampling time to reach maximum observed analyte concentration.

    Time frame: Days 1, 7, 60, 66

  5. Area Under the Plasma Concentration-time Curve From Time Zero to 12 Hours (AUC[0-12h]) for JNJ-64155806

    The AUC(0-12h) is the area under the plasma concentration time curve from time zero to 12 hours.

    Time frame: Days 1, 7, 60, 66

  6. Area Under the Plasma Concentration-time Curve From 12 Hours to 24 Hours (AUC[12-24h]) for JNJ-64155806

    The AUC(12h-24h) is the area under the plasma concentration time curve from time 12 hours to 24 hours.

    Time frame: Days 1, 7, 60, 66

  7. Trough Plasma Concentration (Ctrough) for JNJ-64155806

    Ctrough is the plasma concentration before dosing or at the end of the dosing interval of any dose other than the first dose in a multiple dosing regimen.

    Time frame: Days 5, 6, 7, 64, 65, 66

  8. Average Analyte Concentration (Cavg) for JNJ-64155806

    Cavg is average analyte concentration at steady state, calculated as: AUC24h/24 hours at steady state \[24 hours equal to (=) dosing interval\].

    Time frame: Days 7 and 66

  9. Fluctuation Index (FI) for JNJ-64155806

    FI is the percentage fluctuation (variation between maximum and minimum concentration at steady state).

    Time frame: Days 7 and 66

07

Study locations

1 site
  • Celerion
    Tempe, Arizona 85283, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2017 to primary completion in May 2017, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 13, 2017
First posted
Apr 24, 2017
StartActual
Apr 13, 2017
Primary completionActual
May 26, 2017
CompletionActual
May 26, 2017
Last update
Sep 1, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03126097
Responsible party
Sponsor
First posted
Apr 24, 2017
Start date
Apr 13, 2017
Primary completion
May 26, 2017
Completion
May 26, 2017
Last update
Sep 1, 2017

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion